中华心血管病杂志
中華心血管病雜誌
중화심혈관병잡지
Chinese Journal of Cardiology
2015年
6期
507-510
,共4页
李红霞%张凤文%王瑜丽%刘平%张春雨%冯雪丽%杜军保%金红芳
李紅霞%張鳳文%王瑜麗%劉平%張春雨%馮雪麗%杜軍保%金紅芳
리홍하%장봉문%왕유려%류평%장춘우%풍설려%두군보%금홍방
心动过速%米多君%肾上腺髓质素前体中段肽
心動過速%米多君%腎上腺髓質素前體中段肽
심동과속%미다군%신상선수질소전체중단태
Tachycardia%Midodrine%MR-proADM
目的 研究血浆肾上腺髓质素前体中段肽(midregional fragment of pro-adrenomedullin,MR-proADM)对盐酸米多君治疗儿童及青少年体位性心动过速综合征(postural tachycardia syndrome,POTS)远期疗效的预测价值.方法 选取2007年12月至2010年1月在北京大学第一医院儿科就诊的POTS患者53例,男26例,女27例,平均年龄(14.5±4.5)岁,均采用口服盐酸米多君治疗.以初诊时基线血浆MR-proADM含量将患者分为两组,组1患者(35例)基线血浆MR-proADM含量＞61.5ng/L,组2患者(18例)血浆MR-proADM含量≤61.5 ng/L.随访(67±7)个月,研究不同随访时间两组患者的症状评分,并通过Kaplan-Meier曲线,比较两组患者的无症状生存率.结果 随访60个月时,组1患者的症状积分低于组2(x2=4.985,P＜0.05).随访72个月时,两组患者症状积分差异无统计学意义(x2 =0.004,P ＞0.05).Kaplan-Meier曲线分析表明,组1患者无症状生存率明显高于组2(x2=4.566,P＜0.05).结论 基线血浆MR-proADM含量对于预测盐酸米多君治疗儿童及青少年的远期疗效具有重要价值.
目的 研究血漿腎上腺髓質素前體中段肽(midregional fragment of pro-adrenomedullin,MR-proADM)對鹽痠米多君治療兒童及青少年體位性心動過速綜閤徵(postural tachycardia syndrome,POTS)遠期療效的預測價值.方法 選取2007年12月至2010年1月在北京大學第一醫院兒科就診的POTS患者53例,男26例,女27例,平均年齡(14.5±4.5)歲,均採用口服鹽痠米多君治療.以初診時基線血漿MR-proADM含量將患者分為兩組,組1患者(35例)基線血漿MR-proADM含量＞61.5ng/L,組2患者(18例)血漿MR-proADM含量≤61.5 ng/L.隨訪(67±7)箇月,研究不同隨訪時間兩組患者的癥狀評分,併通過Kaplan-Meier麯線,比較兩組患者的無癥狀生存率.結果 隨訪60箇月時,組1患者的癥狀積分低于組2(x2=4.985,P＜0.05).隨訪72箇月時,兩組患者癥狀積分差異無統計學意義(x2 =0.004,P ＞0.05).Kaplan-Meier麯線分析錶明,組1患者無癥狀生存率明顯高于組2(x2=4.566,P＜0.05).結論 基線血漿MR-proADM含量對于預測鹽痠米多君治療兒童及青少年的遠期療效具有重要價值.
목적 연구혈장신상선수질소전체중단태(midregional fragment of pro-adrenomedullin,MR-proADM)대염산미다군치료인동급청소년체위성심동과속종합정(postural tachycardia syndrome,POTS)원기료효적예측개치.방법 선취2007년12월지2010년1월재북경대학제일의원인과취진적POTS환자53례,남26례,녀27례,평균년령(14.5±4.5)세,균채용구복염산미다군치료.이초진시기선혈장MR-proADM함량장환자분위량조,조1환자(35례)기선혈장MR-proADM함량＞61.5ng/L,조2환자(18례)혈장MR-proADM함량≤61.5 ng/L.수방(67±7)개월,연구불동수방시간량조환자적증상평분,병통과Kaplan-Meier곡선,비교량조환자적무증상생존솔.결과 수방60개월시,조1환자적증상적분저우조2(x2=4.985,P＜0.05).수방72개월시,량조환자증상적분차이무통계학의의(x2 =0.004,P ＞0.05).Kaplan-Meier곡선분석표명,조1환자무증상생존솔명현고우조2(x2=4.566,P＜0.05).결론 기선혈장MR-proADM함량대우예측염산미다군치료인동급청소년적원기료효구유중요개치.
Objective To explore the predictive value of baseline plasma midregional fragment of pro-adrenomedullin level (MR-proADM) on long-term survival of postural tachycardia syndrome (POTS) children treated with midodrine hydrochloride.Methods Fifty-three children (male 26,mean age(14.5 ±4.5) years old) with POTS were included in this study,and all of them were diagnosed as POTS in our department from December 2007 to January 2010.Fifty-three children with POTS were divided into two groups according to the baseline plasma content of MR-proADM.Group Ⅰ consisted of 35 POTS children with plasma content of MR-proADM ＞ 61.5 ng/L,and the group Ⅱ consisted of 18 POTS children with plasma content of MR-proADM ≤ 61.5 ng/L.The mean follow-up time was (67 ± 7) months.The orthostatic intolerance symptom score and the symptom free survival were compared between the 2 groups.Results At the 60 months follow-up,the symptom score of children in group Ⅰ was significantly lower than that in group Ⅱ (x2 =4.985,P ＜ 0.05).At 72 months follow up,the symptom score was similar between the 2 groups (x2 =0.004,P ＞ 0.05) while the symptom free survival of group Ⅰ was significantly higher than that in group Ⅱ (x2 =4.566,P ＜ 0.05).Conclusion The baseline plasma MR-proADM level is value in predicting the long-term survival of POTS children treated with midodrine hydrochloride.
